Ocuphire Pharma Hits New 52-Week High of $5.30, Up 185% Year-Over-Year

Ocuphire Pharma, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 5.30 on March 10, 2026. This achievement marks a remarkable 185.29% increase in the company's stock price over the past year, significantly outperforming the S&P 500, which has seen a gain of 20.78% during the same period. With a market capitalization of USD 234 million, Ocuphire operates in a competitive industry where innovation and strategic positioning are crucial. The company's financial metrics reflect its current standing, with a price-to-book ratio of 39.18. However, it is important to note that Ocuphire is currently loss-making, as indicated by its negative return on equity of -577.66% and a debt-to-equity ratio of -4.99. As Ocuphire Pharma continues to navigate the dynamic landscape of pharmaceuticals and biotechnology, this new high underscores its recent performance and market activity.